Adam Simmons

586 total citations
30 papers, 353 citations indexed

About

Adam Simmons is a scholar working on Psychiatry and Mental health, Pharmacology and Sociology and Political Science. According to data from OpenAlex, Adam Simmons has authored 30 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 8 papers in Pharmacology and 3 papers in Sociology and Political Science. Recurrent topics in Adam Simmons's work include Schizophrenia research and treatment (19 papers), Bipolar Disorder and Treatment (9 papers) and Treatment of Major Depression (7 papers). Adam Simmons is often cited by papers focused on Schizophrenia research and treatment (19 papers), Bipolar Disorder and Treatment (9 papers) and Treatment of Major Depression (7 papers). Adam Simmons collaborates with scholars based in United States, Ireland and Germany. Adam Simmons's co-authors include Ying Jiang, David McDonnell, Lauren DiPetrillo, Bernard L. Silverman, Christine Graham, Christoph U. Correll, René S. Kahn, John W. Newcomer, Yangchun Du and Steven G. Potkin and has published in prestigious journals such as American Journal of Psychiatry, Schizophrenia Bulletin and Schizophrenia Research.

In The Last Decade

Adam Simmons

28 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam Simmons United States 11 239 93 50 45 36 30 353
Rolando Gutierrez-Esteinou United States 8 385 1.6× 110 1.2× 32 0.6× 35 0.8× 45 1.3× 10 466
Kenya A. Costa-Dookhan Canada 9 193 0.8× 36 0.4× 101 2.0× 71 1.6× 38 1.1× 14 373
Niko Seppälä Finland 12 251 1.1× 53 0.6× 61 1.2× 55 1.2× 29 0.8× 20 398
James E. Emanuel United States 8 177 0.7× 27 0.3× 113 2.3× 33 0.7× 25 0.7× 12 300
Astrid Röh Germany 6 188 0.8× 24 0.3× 49 1.0× 22 0.5× 34 0.9× 15 267
Elise A. Weamer United States 10 239 1.0× 45 0.5× 215 4.3× 67 1.5× 16 0.4× 11 395
Kenji Tagai Japan 12 139 0.6× 26 0.3× 88 1.8× 41 0.9× 38 1.1× 50 325
Lovisa Berggren United States 13 178 0.7× 103 1.1× 35 0.7× 21 0.5× 31 0.9× 27 392
Srdjan Stankovic United States 5 103 0.4× 52 0.6× 39 0.8× 18 0.4× 17 0.5× 7 190
Marcos Gómez‐Revuelta Spain 11 228 1.0× 48 0.5× 50 1.0× 14 0.3× 62 1.7× 35 319

Countries citing papers authored by Adam Simmons

Since Specialization
Citations

This map shows the geographic impact of Adam Simmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Simmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Simmons more than expected).

Fields of papers citing papers by Adam Simmons

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Simmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Simmons. The network helps show where Adam Simmons may publish in the future.

Co-authorship network of co-authors of Adam Simmons

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Simmons. A scholar is included among the top collaborators of Adam Simmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Simmons. Adam Simmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simmons, Adam, et al.. (2024). Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients. Frontiers in Psychiatry. 15. 1377174–1377174. 2 indexed citations
2.
Long, Hua, Adam Simmons, Arthur J. Mayorga, et al.. (2024). Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease. Alzheimer s Research & Therapy. 16(1). 235–235. 38 indexed citations
3.
4.
Genge, Angela, Leonard H. van den Berg, Glen Frick, et al.. (2023). Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis. JAMA Neurology. 80(10). 1089–1089. 11 indexed citations
5.
Kahn, René S., John M. Kane, Christoph U. Correll, et al.. (2023). Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness. The Journal of Clinical Psychiatry. 84(3). 12 indexed citations
6.
Correll, Christoph U., Mikkel Højlund, Christine Graham, et al.. (2023). Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis. The International Journal of Neuropsychopharmacology. 26(7). 451–464. 11 indexed citations
7.
Romano, Gary, et al.. (2023). INVOKE‐2: Phase 2 trial of a TREM2 mAb in Early AD. Alzheimer s & Dementia. 19(S13). 1 indexed citations
8.
Meyer, Jonathan M., et al.. (2022). Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. CNS Spectrums. 28(4). 478–481. 5 indexed citations
9.
Simmons, Adam. (2022). The Nubian “King” in Constantinople (1203): Interactions between Nubia and the Mediterranean. Medieval Encounters. 28(3). 242–264.
10.
Citrome, Leslie, Christine Graham, Adam Simmons, et al.. (2021). An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. Neuropsychiatric Disease and Treatment. Volume 17. 2885–2904. 17 indexed citations
11.
Kahn, René S., Bernard L. Silverman, Lauren DiPetrillo, et al.. (2021). A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension. Schizophrenia Research. 232. 45–53. 33 indexed citations
12.
Potkin, Steven G., Jelena Kunovac, Bernard L. Silverman, et al.. (2020). Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia. The Journal of Clinical Psychiatry. 81(2). 47 indexed citations
13.
Brunette, Mary F., Christoph U. Correll, David McDonnell, et al.. (2020). Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder. The Journal of Clinical Psychiatry. 81(2). 18 indexed citations
14.
15.
Correll, Christoph U., John W. Newcomer, Bernard L. Silverman, et al.. (2020). 100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study. CNS Spectrums. 25(2). 265–265.
16.
Citrome, Leslie, Stephanie S. O’Malley, David McDonnell, et al.. (2019). Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.. PubMed. 16(5-6). 15–21. 4 indexed citations
17.
18.
McDonnell, David, Steven G. Potkin, Adam Simmons, et al.. (2018). F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA. Schizophrenia Bulletin. 44(suppl_1). S312–S312. 1 indexed citations
19.
Simmons, Adam, David McDonnell, Ying Jiang, Christine Graham, & Bernard L. Silverman. (2018). S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER. Schizophrenia Bulletin. 44(suppl_1). S413–S414. 1 indexed citations
20.
Simmons, Adam. (2009). Encyclopedia of Adaptations in the Natural World. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rolando Gutierrez-Esteinou Breakdown of academic impact, for papers by Kenya A. Costa-Dookhan Breakdown of academic impact, for papers by Niko Seppälä Breakdown of academic impact, for papers by James E. Emanuel Breakdown of academic impact, for papers by Astrid Röh Breakdown of academic impact, for papers by Elise A. Weamer Breakdown of academic impact, for papers by Kenji Tagai Breakdown of academic impact, for papers by Lovisa Berggren Breakdown of academic impact, for papers by Srdjan Stankovic Breakdown of academic impact, for papers by Marcos Gómez‐Revuelta
Rankless by CCL
2026